REHOVOT, Israel--(BUSINESS WIRE)--Proteologics Ltd., a leader in the ubiquitin system drug discovery, announces the licensing of three programs to Teva Pharmaceutical Industries Ltd. Under the agreement, Proteologics will discover and conduct early development of cancer treatments, while Teva will proceed with later stages of development, manufacturing and worldwide commercialization of the products.
